Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines.
antigens
cancer vaccine
cell authentication
mass spectrometry
proteomic footprint
quality control
vaccination
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
16 Feb 2023
16 Feb 2023
Historique:
received:
08
12
2022
revised:
31
01
2023
accepted:
13
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
In omics sciences, many compounds are measured simultaneously in a sample in a single run. Such analytical performance opens up prospects for improving cellular cancer vaccines and other cell-based immunotherapeutics. This article provides an overview of proteomics technology, known as cell proteomic footprinting. The molecular phenotype of cells is highly variable, and their antigenic profile is affected by many factors, including cell isolation from the tissue, cell cultivation conditions, and storage procedures. This makes the therapeutic properties of cells, including those used in vaccines, unpredictable. Cell proteomic footprinting makes it possible to obtain controlled cell products. Namely, this technology facilitates the cell authentication and quality control of cells regarding their molecular phenotype, which is directly connected with the antigenic properties of cell products. Protocols for cell proteomic footprinting with their crucial moments, footprint processing, and recommendations for the implementation of this technology are described in this paper. The provided footprints in this paper and program source code for their processing contribute to the fast implementation of this technology in the development and manufacturing of cell-based immunotherapeutics.
Identifiants
pubmed: 36839983
pii: pharmaceutics15020661
doi: 10.3390/pharmaceutics15020661
pmc: PMC9963030
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : The Ministry of Education and Science of the Russian Federation
ID : Agreement No. 075-15-2021-933, unique project ID: RF00121X0004
Références
Physiol Genomics. 2001 Dec 21;7(2):95-6
pubmed: 11773595
J Immunother. 2008 Jan;31(1):72-80
pubmed: 18157014
J Transl Med. 2007 Sep 14;5:43
pubmed: 17868452
Chin Med J (Engl). 2006 Feb 20;119(4):275-81
pubmed: 16537021
BMC Genomics. 2014 Oct 03;15:847
pubmed: 25277546
Curr Opin Mol Ther. 2010 Feb;12(1):14-20
pubmed: 20140812
Nature. 1997 Nov 27;390(6658):404-7
pubmed: 9389480
Eur J Cancer. 1993;29A(15):2158-60
pubmed: 8297657
Neoplasia. 2000 Sep-Oct;2(5):449-59
pubmed: 11191112
Cytotechnology. 2002 Jul;39(2):69-74
pubmed: 19003294
J Cell Sci. 2003 Mar 15;116(Pt 6):1013-22
pubmed: 12584245
Science. 2000 Aug 18;289(5482):1197-202
pubmed: 10947988
Methods Mol Biol. 2020;2110:47-58
pubmed: 32002900
Hum Vaccin Immunother. 2013 Jan;9(1):198-209
pubmed: 23442592
Nature. 2001 May 17;411(6835):375-9
pubmed: 11357145
Circ Res. 2007 Feb 2;100(2):158-73
pubmed: 17272818
Front Immunol. 2021 Feb 17;11:615240
pubmed: 33679703
J Urol. 2002 May;167(5):1995-2000
pubmed: 11956426
J Cell Sci. 2013 Sep 15;126(Pt 18):4061-7
pubmed: 23970414
Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10988-E10997
pubmed: 30373828
Front Immunol. 2021 Mar 30;12:627932
pubmed: 33859638
In Vitro Cell Dev Biol Anim. 2006 Mar-Apr;42(3-4):58-62
pubmed: 16759149
J Clin Microbiol. 2011 Mar;49(3):887-92
pubmed: 21209160
Tissue Eng. 2001 Apr;7(2):211-28
pubmed: 11304456
Cancer Sci. 2015 Feb;106(2):134-42
pubmed: 25483888
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9495-9
pubmed: 7937795
Br J Cancer. 2004 Jan 26;90(2):476-82
pubmed: 14735196
Int J Cancer. 2022 Oct 15;151(8):1195-1215
pubmed: 35603909
J Clin Oncol. 1990 Nov;8(11):1858-67
pubmed: 2230873
Bioact Mater. 2022 Oct 26;22:491-517
pubmed: 36330160
Nat Immunol. 2017 May;18(5):583-593
pubmed: 28263321
Nat Rev Cancer. 2003 Jun;3(6):453-8
pubmed: 12778135
J Immunother Cancer. 2015 Nov 17;3:48
pubmed: 26579225
Clin Cancer Res. 1996 Jan;2(1):21-8
pubmed: 9816085
J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
pubmed: 1688381
J Clin Oncol. 2000 Jan;18(1):148-57
pubmed: 10623705
Hepatogastroenterology. 2002 May-Jun;49(45):691-3
pubmed: 12063971
Front Immunol. 2019 Mar 14;10:467
pubmed: 30923527
FEMS Microbiol Rev. 2012 Mar;36(2):380-407
pubmed: 22092265
J Immunother (1991). 2001 May;24(3):205-211
pubmed: 11395635
Cancers (Basel). 2023 Jan 04;15(2):
pubmed: 36672284
Clin Cancer Res. 2012 Feb 1;18(3):882-9
pubmed: 22156611
Front Oncol. 2022 Feb 11;12:800028
pubmed: 35223480
Cureus. 2022 Oct 12;14(10):e30210
pubmed: 36381887
Nucleic Acids Res. 2021 Jan 8;49(D1):D947-D955
pubmed: 32663312
Cancer Res. 1999 Oct 1;59(19):5002-11
pubmed: 10519415
Int J Cancer. 1999 Nov 12;83(4):555-63
pubmed: 10508494
Cancer Microenviron. 2012 Dec;5(3):333-44
pubmed: 22562695
Int J Mol Sci. 2022 Apr 15;23(8):
pubmed: 35457221
Nat Rev Mol Cell Biol. 2000 Oct;1(1):72-6
pubmed: 11413492
Mol Cell Proteomics. 2012 Feb;11(2):M111.014480
pubmed: 22074704
J Cancer. 2018 Apr 19;9(10):1773-1781
pubmed: 29805703
Annu Rev Anal Chem (Palo Alto Calif). 2008;1:71-93
pubmed: 20636075
Vaccine. 2001 Mar 21;19(17-19):2576-82
pubmed: 11257395
J Immunol. 2003 Mar 15;170(6):3162-70
pubmed: 12626574
Turk J Med Sci. 2022 Jun;52(3):834-840
pubmed: 36326336
J Transl Med. 2022 Oct 31;20(1):496
pubmed: 36316782
Rapid Commun Mass Spectrom. 2009 Mar;23(5):680-2
pubmed: 19184978
Semin Oncol. 1997 Apr;24(2):203-18
pubmed: 9129690
Pharmaceutics. 2022 Aug 17;14(8):
pubmed: 36015348
J Surg Res. 2005 May 1;125(1):56-67
pubmed: 15836851
Int J Mol Sci. 2017 Jun 30;18(7):
pubmed: 28665313
Cytotechnology. 2006 Jun;51(2):45-50
pubmed: 19002894
Nature. 2000 Jan 27;403(6768):356
pubmed: 10667765
Nature. 2022 Aug;608(7922):397-404
pubmed: 35922511
Anticancer Res. 2000 Jul-Aug;20(4):2665-76
pubmed: 10953341
Trends Genet. 2008 Oct;24(10):481-4
pubmed: 18786740
Proteomics. 2022 Nov 16;:e2200132
pubmed: 36382392
Nature. 2009 Feb 19;457(7232):935-6
pubmed: 19225471
Eur J Clin Microbiol Infect Dis. 2023 Feb;42(2):153-159
pubmed: 36469165
In Vitro Cell Dev Biol Anim. 2004 Jul-Aug;40(7):211-5
pubmed: 15638703
Brief Bioinform. 2021 Mar 22;22(2):1620-1638
pubmed: 32047889
J Embryol Exp Morphol. 1980 Oct;59:145-55
pubmed: 6260888
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
J Sep Sci. 2022 Aug;45(16):3150-3168
pubmed: 35770343
Mass Spectrom (Tokyo). 2017;6(Spec Iss):S0057
pubmed: 28573082
Mol Cancer. 2021 Oct 11;20(1):131
pubmed: 34635121
Circ Res. 2007 Feb 2;100(2):174-90
pubmed: 17272819
Nature. 1997 Oct 9;389(6651):555-6
pubmed: 9335493
Biochim Biophys Acta. 1976 Apr 5;426(4):630-7
pubmed: 1259987
J Clin Microbiol. 2022 Nov 16;60(11):e0081222
pubmed: 36286489
J Pharm Biomed Anal. 2018 Aug 5;157:122-136
pubmed: 29787965
J Cancer. 2010 Nov 29;1:230-41
pubmed: 21151581
Molecules. 2020 Oct 17;25(20):
pubmed: 33080897
Antioxidants (Basel). 2022 Aug 30;11(9):
pubmed: 36139791
Sci China Life Sci. 2022 Dec 2;:
pubmed: 36469218
Antioxidants (Basel). 2022 Feb 28;11(3):
pubmed: 35326131
J Natl Cancer Inst. 2004 Feb 18;96(4):326-31
pubmed: 14970281
Vaccines (Basel). 2019 Nov 17;7(4):
pubmed: 31744189
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):20-5
pubmed: 12518051
Cancer Immunol Immunother. 2007 Jan;56(1):88-94
pubmed: 16622680
J Proteome Res. 2013 Dec 6;12(12):5666-80
pubmed: 24116745
Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
Cancers (Basel). 2022 Aug 12;14(16):
pubmed: 36010899
Int J Cancer. 2010 Jul 1;127(1):1-8
pubmed: 20143388
Exp Cell Res. 1961 Dec;25:585-621
pubmed: 13905658
Int J Mol Sci. 2021 Dec 04;22(23):
pubmed: 34884942
Cancers (Basel). 2021 Feb 12;13(4):
pubmed: 33673325
Mol Biother. 1988;1(1):30-6
pubmed: 2855788
Nat Rev Microbiol. 2013 Aug;11(8):574-85
pubmed: 24020074
J Pharm Pharm Sci. 2007;10(2):144-52
pubmed: 17706173
Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7656-8
pubmed: 11438719
Am J Pathol. 2008 May;172(5):1381-90
pubmed: 18403594